Takeda Pharmaceutical Company Limited (FRA:TKD)

Market Cap	38.68B
Revenue (ttm)	26.44B
Net Income (ttm)	808.10M
Shares Out	n/a
EPS (ttm)	0.50
PE Ratio	47.86
Forward PE	n/a
Dividend	1.21 (4.84%)
Ex-Dividend Date	Mar 28, 2025

Volume	971
Average Volume	172
Open	24.67
Previous Close	24.95
Day's Range	24.39 - 24.75
52-Week Range	23.54 - 28.29
Beta	n/a
RSI	33.94
Earnings Date	Oct 30, 2025

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2024, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY